Journal of Experimental Medicine, Vol 177, 989-998, Copyright © 1993 by Rockefeller University Press

ARTICLES

Melanoma cells and normal melanocytes share antigens recognized by HLA- A2-restricted cytotoxic T cell clones from melanoma patients

A Anichini, C Maccalli, R Mortarini, S Salvi, A Mazzocchi, P Squarcina, M Herlyn and G Parmiani
Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy.

HLA-A2-restricted, CD3+, CD8+, alpha/beta+ cytotoxic T cell (CTL) clones were isolated from peripheral blood (PBL) or tumor infiltrating lymphocytes (TIL) of two HLA-A2+ melanoma patients (9742 and 5810), to evaluate the possible recognition of autologous melanoma and of allogeneic HLA-A2-matched normal melanocytes. These CTL clones lysed not only fresh and cultured autologous melanoma cells, but also allogeneic HLA-A2+, but not HLA-A2-, normal melanocytes. The lysis of autologous neoplastic cells and of melanocytes could be inhibited by an anti-HLA-A2 monoclonal antibody (mAb). Lysis of the normal melanocytes was not dependent on the presence of human or fetal calf serum in the culture medium. HLA-A2-restricted CTL clones recognized not only proliferating melanocytes cultured in complete melanocyte medium, but also melanocytes made quiescent by culture for up to 6 d in a basal medium devoid of exogenous factors such as phorbol ester (O- tetradecanoyl phorbol 13-acetate [TPA]), epidermal growth factor, insulin, and pituitary extracts. Analysis of specificity of four CTL clones (A75, A83, A94, and 119) from patient 9742, performed on a panel of 39 targets, indicated that the three HLA-A2-restricted CTL (A75, A83, and A94) lysed all but one of nine allogeneic melanomas expressing the HLA-A2 molecule with no reactivity on nine HLA-A2- allogeneic melanomas. Only a few instances of borderline reactivity were seen by the same effectors on 21 targets of nonmelanocyte lineage, including 12 carcinomas of different histology, four Epstein-Barr virus-transformed B cells (lymphoblastoid cell lines [LCL]), including the autologous LCL, four lines of normal fibroblasts, and normal kidney cells. Lack of reactivity on allogeneic targets of nonmelanocyte lineage occurred in spite of expression of HLA-A2 on 14 of these targets as determined by conventional tissue typing and cytofluorimetric analysis with four different anti-HLA-A2 mAb. These data indicate that tissue-related antigens can be expressed on normal and neoplastic cells of the melanocyte lineage and can be recognized in association with HLA-A2 by CTL clones from melanoma patients.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

• Parmiani, G., De Filippo, A., Novellino, L., Castelli, C. (2007). Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials. J. Immunol. 178: 1975-1979 [Abstract] [Full Text]  
• Sensi, M., Nicolini, G., Zanon, M., Colombo, C., Molla, A., Bersani, I., Lupetti, R., Parmiani, G., Anichini, A. (2005). Immunogenicity without Immunoselection: A Mutant but Functional Antioxidant Enzyme Retained in a Human Metastatic Melanoma and Targeted by CD8+ T Cells with a Memory Phenotype. Cancer Res. 65: 632-640 [Abstract] [Full Text]  
• Dorrschuck, A., Schmidt, A., Schnurer, E., Gluckmann, M., Albrecht, C., Wolfel, C., Lennerz, V., Lifke, A., Di Natale, C., Ranieri, E., Gesualdo, L., Huber, C., Karas, M., Wolfel, T., Herr, W. (2004). CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression. Blood 104: 2591-2599 [Abstract] [Full Text]  
• Denkberg, G., Lev, A., Eisenbach, L., Benhar, I., Reiter, Y. (2003). Selective Targeting of Melanoma and APCs Using a Recombinant Antibody with TCR-Like Specificity Directed Toward a Melanoma Differentiation Antigen. J. Immunol. 171: 2197-2207 [Abstract] [Full Text]  
• Denkberg, G., Klechevsky, E., Reiter, Y. (2002). Modification of a Tumor-Derived Peptide at an HLA-A2 Anchor Residue Can Alter the Conformation of the MHC-Peptide Complex: Probing with TCR-Like Recombinant Antibodies. J. Immunol. 169: 4399-4407 [Abstract] [Full Text]  
• Denkberg, G., Cohen, C. J., Lev, A., Chames, P., Hoogenboom, H. R., Reiter, Y. (2002). Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 99: 9421-9426 [Abstract] [Full Text]  
• Armstrong, A C, Hawkins, R E (2001). Vaccines in oncology: background and clinical potential. Br. J. Radiol. 74: 991-1002 [Abstract] [Full Text]  
• Wang, F., Bade, E., Kuniyoshi, C., Spears, L., Jeffery, G., Marty, V., Groshen, S., Weber, J. (1999). Phase I Trial of a MART-1 Peptide Vaccine with Incomplete Freund's Adjuvant for Resected High-Risk Melanoma. Clin. Cancer Res. 5: 2756-2765 [Abstract] [Full Text]  
• Butterfield, L. H., Jilani, S. M., Chakraborty, N. G., Bui, L. A., Ribas, A., Dissette, V. B., Lau, R., Gamradt, S. C., Glaspy, J. A., McBride, W. H., Mukherji, B., Economou, J. S. (1998). Generation of Melanoma-Specific Cytotoxic T Lymphocytes by Dendritic Cells Transduced with a MART-1 Adenovirus. J. Immunol. 161: 5607-5613 [Abstract] [Full Text]  
• Tureci, O., Sahin, U., Zwick, C., Koslowski, M., Seitz, G., Pfreundschuh, M. (1998). Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc. Natl. Acad. Sci. USA 95: 5211-5216 [Abstract] [Full Text]  
• Cox, A., Skipper, J, Chen, Y, Henderson, R., Darrow, T., Shabanowitz, J, Engelhard, V., Hunt, D., Slingluff, C. Jr (1994). Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716-719 [Abstract]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS